Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.

Blood cancer journal·2026
Same author

Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial.

Nature communications·2026
Same author

Chinese guidelines on comprehensive assessment of clinical practice in hematopoietic stem cell transplantation Δ.

Journal of cancer research and therapeutics·2026
Same author

Treatment Patterns and Clinical Outcomes After Immunotherapy Failure in Patients With Natural Killer/T-Cell Lymphoma.

American journal of hematology·2026
Same author

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2026
Same author

Assessing patient perspectives on enrollment in lymphoma clinical trials.

Cancer·2026

Related Experiment Video

Updated: May 4, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

14.2K

Accelerated therapeutic progress in diffuse large B cell lymphoma.

Qingqing Cai1, Jason Westin, Kai Fu

  • 1Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, China.

Annals of Hematology
|December 31, 2013
PubMed
Summary
This summary is machine-generated.

Diffuse large B cell lymphoma (DLBCL) is a common, heterogeneous cancer. Novel agents offer promise for treating relapsed DLBCL, improving outcomes for patients with this challenging non-Hodgkin lymphoma.

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.0K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

951

Related Experiment Videos

Last Updated: May 4, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

14.2K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.0K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

951

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Diffuse large B cell lymphoma (DLBCL) is the most prevalent non-Hodgkin lymphoma globally.
  • DLBCL exhibits significant clinical, biological, and pathological heterogeneity, leading to varied patient outcomes.
  • Current immunochemotherapy (rituximab plus chemotherapy) has improved outcomes but does not achieve cures in all patients.

Purpose of the Study:

  • To summarize prognostic factors and current treatments for DLBCL.
  • To review the potential of novel therapeutic agents for DLBCL.
  • To discuss future directions for clinical trials in DLBCL management.

Main Methods:

  • Literature review of existing data on DLBCL.
  • Analysis of prognostic factors and treatment strategies.
  • Evaluation of novel agents including lenalidomide, carfilzomib, and ibrutinib.

Main Results:

  • Immunochemotherapy has improved DLBCL outcomes.
  • Relapsed DLBCL treatment involves salvage therapy and stem cell transplantation, with a subset remaining incurable.
  • Understanding DLBCL subtypes and gene expression aids in identifying targeted therapies.

Conclusions:

  • Novel agents and rational combinations hold significant promise for achieving cures in DLBCL.
  • Subtype-specific therapies targeting identified molecular pathways are a key future direction.
  • Continued research and clinical trials are essential to advance DLBCL treatment and cure rates.